Loring Wolcott & Coolidge Fiduciary Advisors LLP Gh Research PLC Transaction History
Loring Wolcott & Coolidge Fiduciary Advisors LLP
- $10.3 Billion
- Q1 2025
A detailed history of Loring Wolcott & Coolidge Fiduciary Advisors LLP transactions in Gh Research PLC stock. As of the latest transaction made, Loring Wolcott & Coolidge Fiduciary Advisors LLP holds 2,000 shares of GHRS stock, worth $25,220. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,000
Previous 2,000
-0.0%
Holding current value
$25,220
Previous $14,000
57.14%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding GHRS
# of Institutions
42Shares Held
38.5MCall Options Held
5KPut Options Held
5.5K-
Bvf Inc San Francisco, CA8.83MShares$111 Million4.28% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.94MShares$87.6 Million1.59% of portfolio
-
Lynx1 Capital Management LP San Juan, PR6.44MShares$81.3 Million26.28% of portfolio
-
Rtw Investments, LP New York, NY5.5MShares$69.4 Million0.99% of portfolio
-
Cormorant Asset Management, LP Boston, MA2.01MShares$25.3 Million2.35% of portfolio
About GH Research PLC
- Ticker GHRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,020,800
- Market Cap $656M
- Description
- GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH0...